We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Lazertinib
Synonyms
Therapy Description

Lazcluze (lazertinib) is an irreversible protein kinase inhibitor with selective activity against mutant EGFR, which may lead to growth inhibition of EGFR-mutant tumor cells and reduced toxicity (PMID: 30670498, PMID: 32599977). Lazcluze (lazertinib) is FDA approved in combination with Rybrevant (amivantamab-vmjw) as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Lazertinib Lazcluze GNS 1480|YH25448|JNJ-73841937|JNJ73841937|JNJ 73841937|YH 25448|YH-25448 EGFR Inhibitor 3rd gen 26 Lazcluze (lazertinib) is an irreversible protein kinase inhibitor with selective activity against mutant EGFR, which may lead to growth inhibition of EGFR-mutant tumor cells and reduced toxicity (PMID: 30670498, PMID: 32599977). Lazcluze (lazertinib) is FDA approved in combination with Rybrevant (amivantamab-vmjw) as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov)

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT06667076 Phase II Lazertinib Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS) Recruiting USA 1
NCT04075396 Phase Ib/II Lazertinib A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Completed USA | GBR | ESP 0
NCT04487080 Phase III Amivantamab-vmjw + Lazertinib Lazertinib Osimertinib A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 12
NCT04077463 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium Amivantamab-vmjw Lazertinib A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2) Active, not recruiting USA | ITA | FRA | ESP | DEU 5


Additional content available in Icon for CKB-BoostCKB BOOST